vegassports-odds.com
vegassports-odds.com October 17, 2017


What Are Analysts Report About Repros Therapeutics Inc. (RPRX)

12 October 2017, 05:08 | Melvin Schneider

Repros Therapeutics (NASDAQ:RPRX) shares traded on 41.51% above secure line and closed at $0.75. RPRX has diverse figures for different time frames; starting from week's performance it has positive performance of 104.73% in last five regular trading sessions. It has a market cap of $27.26 Million. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 2.23% with $36.34 Million sitting short, betting on future declines.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Repros Therapeutics (NASDAQ:RPRX) high price target of $5.5 and with a conservative view have low price target of $5.5. Looking at the stock's movement on the chart, Repros Therapeutics Inc. recorded a 52-week high of $2.18. The latest exchange of 2.85 Million shares is below its average trading activity of 291.76 Million shares. Unusual volume shows something has likely happened in the stock-such as a news release or traders have become anxious or euphoric about the stock's potential. However, 149.58% over the last one month, 35.33% for the last quarter and year to date performance stands at -43.18%. The stock realized a fall in short interest between August 31, 2017 and September 15, 2017 of -32.24%. Share performance for the month is now at -54.50%. Its weekly performance showed upward trend of 65.63 percent. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. The percentage of shares being held by the company management was 0.2% while institutional stake was 20.1%.

Liquidity ratios help investors to determine a company's ability to pay off its debts. Its book value per share for the most recent quarter is $-0.01 while its price to book ratio for the same period is 0, as for as the company's cash per share for the most recent quarter is $0.1, however its price to cash per share ratio for the same period is 6.64.

Repros Therapeutics Inc. (RPRX) has a Return on Assets of -212.1 percent, Return on Investment of 0 percent and a Return on Equity of -412.4 percent. The 50 day moving average moved up $0.30 whereas the 200 day average was up by +13.7721%.

The company's diluted EPS for trailing twelve months was -0.63. Revenue during the quarter was $39.84 billion, representing -2% growth from $40.52 billion in year-ago quarter.

Sensex Zooms 135 Points at 31969, Nifty Above 10000
Japan's Nikkei rose 0.47 per cent while Hong Kong's Hang Seng moved up 0.17 per cent in early trade today. The 30-share Sensex after opening higher settled up 348.23 points, or 1.09 per cent, at 32,182.22.

Cabot Oil & Gas Corp (NYSE:COG) Institutional Investor Sentiment
Zacks Investment Research cut Cabot Oil & Gas Corporation from a hold rating to a sell rating in a report on Tuesday, July 18th. Patten Group Inc Inc invested 0.46% of its portfolio in Williams Companies Inc (NYSE:WMB). (NASDAQ:QCOM).

Arsene Wenger: I could sell Mesut Ozil and Alexis Sanchez in January
After Brazil's 3-0 win over Chile this week, Alves said: "He is wanted by many teams". I hope he'll be happy, wherever he goes.

RPRX's mean Piotroski F-Score: 3 in the past 7 years. A rating of 4 or 5 would represent a Sell recommendation.

Quarterly Earnings Growth on year-over-year basis stands at 56 percent. The company posted an earnings surprise of 63.6%.

This company has been competing with others in the Healthcare space and offers its own combination of interesting factors Repros Therapeutics Inc. The typical day in the last two weeks has seen about a 16.33% volatility. On average, analysts predict that Repros Therapeutics will post ($0.76) EPS for the current fiscal year.

The clinical development expenses pertaining to enclomiphene dropped for the reported quarter as against the prior year period, due to lower expenses related with its Phase II proof of concept trial, ZA-205. (RPRX)-0 analysts issued Buy for the stock, 1 analysts gave Outperform rating, 0 think it's a Hold, 0 issued Underperform, while 0 analyst gave a Sell rating. If Repros Therapeutics Inc. However, the institutional investors are observed to own 20.10% of the total shares.



Other News

Trending Now

Arsene Wenger: 'Jack Wilshere showing best form for a long time'
The Gunners star, 25, last played for the Three Lions in the disastrous 2-1 loss to Iceland in the Euro 2016 knockout stage. Arsenal acquired "world class" talent in Alexandre Lacazette and a "monster" in Sead Kolasinac , says Jack Wilshere .

VICTOR GARBER Exits DC's LEGENDS OF TOMORROW As Series Regular
Garber takes over the role from David Hyde Pierce (with Peters stepping in for Bette Midler.) His first show is January 20. " DC's Legends of Tomorrow " season 3 may be the final regular season for one of the show's main cast members.

Arsenal defender Skhodran Mustafi ruled out for at least a month
"We've lost Mustafi for about four to six weeks", said Gunners manager Wenger. Wenger explained: "Koscielny has a definite final test tomorrow".

Mysterious hole the size of ME opens in Antarctica
Areas of open water enveloped by ice, such as this hole are known as polynias and are formed in the coastal areas of Antarctica. Moore says they are working to understand what is triggering the formation of these holes again after so many years.